Oceania Healthcare Set for Potential Upside; 'Could Re-rate Sooner', Jarden Says

MT Newswires Live

Nov 27, 2024

Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.

The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.

Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.

Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.

Faster realization of the fees, progress on further development execution, and inventory sell-down "could re-rate OCA sooner, taking into account other factors," Jarden added.

The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2486891490"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486891490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486891490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486891490","market":"hk","top_or_hot":-1,"title":"Oceania Healthcare Set for Potential Upside; 'Could Re-rate Sooner', Jarden Says","media":"MT Newswires Live","content":"<html><body><p> Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.</p><p>The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.</p><p>Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.</p><p>Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.</p><p>Faster realization of the fees, progress on further development execution, and inventory sell-down \"could re-rate OCA sooner, taking into account other factors,\" Jarden added.</p><p>The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oceania Healthcare Set for Potential Upside; 'Could Re-rate Sooner', Jarden Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOceania Healthcare Set for Potential Upside; 'Could Re-rate Sooner', Jarden Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-27 13:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.</p><p>The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.</p><p>Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.</p><p>Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.</p><p>Faster realization of the fees, progress on further development execution, and inventory sell-down \"could re-rate OCA sooner, taking into account other factors,\" Jarden added.</p><p>The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7113","symbol_name":"保健护理机构","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486891490","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486891490","pubTimestamp":1732685836,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oceania Healthcare's  progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.Faster realization of the fees, progress on further development execution, and inventory sell-down \"could re-rate OCA sooner, taking into account other factors,\" Jarden added.The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7113":"保健护理机构","OCA.AU":"OCEANIA HEALTHCARE LTD","HCSG":"Healthcare Svcs Group Inc","BK4137":"综合支持服务"},"translate_title":"大洋洲医疗保健面临潜在上涨空间；贾登表示，“可以更快地重新评级”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"OCA.AU":0.9},"content_text":"Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.Faster realization of the fees, progress on further development execution, and inventory sell-down \"could re-rate OCA sooner, taking into account other factors,\" Jarden added.The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}